Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000523583 | SCV000617296 | pathogenic | not provided | 2023-06-14 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 29758347, 20921020, 31736247, 31618753, 36073289) |
Labcorp Genetics |
RCV000050204 | SCV001214723 | pathogenic | Cohen syndrome | 2023-10-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg1696*) in the VPS13B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in VPS13B are known to be pathogenic (PMID: 15141358, 16648375, 20461111). This variant is present in population databases (rs386834093, gnomAD 0.006%). This premature translational stop signal has been observed in individual(s) with Cohen syndrome (PMID: 20921020, 29758347). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 56803). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV001267010 | SCV001445191 | pathogenic | Inborn genetic diseases | 2018-02-27 | criteria provided, single submitter | clinical testing | |
Center for Genomic Medicine, |
RCV000050204 | SCV004804980 | pathogenic | Cohen syndrome | 2024-03-17 | criteria provided, single submitter | research | |
Juha Muilu Group; Institute for Molecular Medicine Finland |
RCV000050204 | SCV000082780 | probable-pathogenic | Cohen syndrome | no assertion criteria provided | not provided | Converted during submission to Likely pathogenic. |